Dipankar Yettapu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dipankar Yettapu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Aditya Mazmudar
MedStar Orthopedic Institute, MedStar Georgetown University Hospital, Washington, DC
1 shared publication - Daniel Kwangwon Park
Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, Illinois
1 shared publication Jacob G. Calcei
School of Medicine, Case Western Reserve University, Cleveland, OH, USA
1 shared publicationJohn M. Apostolakos
School of Medicine, Case Western Reserve University, Cleveland, OH, USA
1 shared publication- Kern Singh
Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL, USA
1 shared publication - Mahan Miryala
School of Medicine, Case Western Reserve University, Cleveland, OH, USA
1 shared publication
Latest Publications
- Open Access
- 19 November 2026
- Published by SAGE Publications in HSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery
Chatbots and Social Media-Embedded AI Assistants Provide Inconsistent Information on the Use of Unregulated Peptides Marketed for Musculoskeletal Recovery
Background: Unregulated peptides like BPC-157 are heavily marketed for musculoskeletal recovery despite the lack of U.S. Food and Drug Administration approval and minimal evidence from human trials. With peptide content widely promoted on social media, patients increasingly consult artificial intelligence (AI) tools to evaluate claims regarding the efficacy of these products. Purpose: We sought to compare the accuracy, completeness, and readability of AI-generated information on unregulated peptides for musculoskeletal recovery across dedicated AI tools and social-media-embedded assistants. Methods: We performed a cross-sectional content analysis study of AI outputs in response to 4 standardized questions about unapproved peptide use. Seven dedicated AI tools (ChatGPT, Gemini, Claude, OpenEvidence, Elicit, Undermind, and Consensus.ai) and 4 social-media assistants (Instagram, Facebook, TikTok, and X) were queried in May 2026. Readability was assessed using a composite of 4 grade-level formulas. Two evidence-anchored questions were scored by 3 blinded reviewers (2 orthopedic surgeons and 1 immunopathologist) using the validated Quality Assessment of Medical Artificial Intelligence (QAMAI) instrument (6-30) for the 7 dedicated AI tools but not for the 4 social media assistants. Results: Mean QAMAI score across the dedicated tools was 21.6/30 (good), ranging from 17.8 (Undermind, fair) to 25.3 (Claude, very good). Among dedicated tools, pooled QAMAI domain scores were highest for accuracy (4.0/5) and lowest for completeness (3.3/5). Among social-media assistants, X and Facebook were accurate, TikTok was mixed, and Instagram (Meta AI) spread misinformation, claiming BPC-157 accelerates recovery and endorsing post-surgical use. All 11 tools produced outputs at the college level (mean grade: 13.9), above the sixth-to-eighth-grade target for patient materials, with no correlation between quality and readability. Conclusion: Our analysis suggests that AI tools cannot substitute for clinical counseling on unregulated peptides. The accuracy subscore was generally strong, but completeness and readability remained poor. Medical societies should partner with AI developers to standardize evidence-anchored responses and prevent patient harm. Level of Evidence: Level IV: observational content analysis study.
- 19 November 2026
- Published by SAGE Publications in HSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery
Open AccessChatbots and Social Media-Embedded AI Assistants Provide Inconsistent Information on the Use of Unregulated Peptides Marketed for Musculoskeletal Recovery
Background: Unregulated peptides like BPC-157 are heavily marketed for musculoskeletal recovery despite the lack of U.S. Food and Drug Administration approval and minimal evidence from human trials. With peptide content widely promoted on social media, patients increasingly consult artificial intelligence (AI) tools to evaluate claims regarding the efficacy of these products. Purpose: We sought to compare the accuracy, completeness, and readability of AI-generated information on unregulated peptides for musculoskeletal recovery across dedicated AI tools and social-media-embedded assistants. Methods: We performed a cross-sectional content analysis study of AI outputs in response to 4 standardized questions about unapproved peptide use. Seven dedicated AI tools (ChatGPT, Gemini, Claude, OpenEvidence, Elicit, Undermind, and Consensus.ai) and 4 social-media assistants (Instagram, Facebook, TikTok, and X) were queried in May 2026. Readability was assessed using a composite of 4 grade-level formulas. Two evidence-anchored questions were scored by 3 blinded reviewers (2 orthopedic surgeons and 1 immunopathologist) using the validated Quality Assessment of Medical Artificial Intelligence (QAMAI) instrument (6-30) for the 7 dedicated AI tools but not for the 4 social media assistants. Results: Mean QAMAI score across the dedicated tools was 21.6/30 (good), ranging from 17.8 (Undermind, fair) to 25.3 (Claude, very good). Among dedicated tools, pooled QAMAI domain scores were highest for accuracy (4.0/5) and lowest for completeness (3.3/5). Among social-media assistants, X and Facebook were accurate, TikTok was mixed, and Instagram (Meta AI) spread misinformation, claiming BPC-157 accelerates recovery and endorsing post-surgical use. All 11 tools produced outputs at the college level (mean grade: 13.9), above the sixth-to-eighth-grade target for patient materials, with no correlation between quality and readability. Conclusion: Our analysis suggests that AI tools cannot substitute for clinical counseling on unregulated peptides. The accuracy subscore was generally strong, but completeness and readability remained poor. Medical societies should partner with AI developers to standardize evidence-anchored responses and prevent patient harm. Level of Evidence: Level IV: observational content analysis study.
- 1 October 2026
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
Denying and Delaying Indicated Care: The True Cost
Cost in health care is not simply the dollar amount of a transaction. When a claim for indicated surgery is denied or delayed, savings are not guaranteed and patient outcomes likely worsen. Delays resulting from prior authorization create an administrative burden, and patients bear the burden of prolonged conservative care, lost workforce participation, and added psychological toll. Delaying or denying indicated surgery does not reduce cost; it simply redistributes it.
- 1 October 2026
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
Denying and Delaying Indicated Care: The True Cost
Cost in health care is not simply the dollar amount of a transaction. When a claim for indicated surgery is denied or delayed, savings are not guaranteed and patient outcomes likely worsen. Delays resulting from prior authorization create an administrative burden, and patients bear the burden of prolonged conservative care, lost workforce participation, and added psychological toll. Delaying or denying indicated surgery does not reduce cost; it simply redistributes it.